ID   BFTC-905-DOXO-II
AC   CVCL_4V69
DR   cancercelllines; CVCL_4V69
DR   Wikidata; Q54796208
RX   PubMed=25566959;
CC   Population: Chinese; Taiwan.
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.673-2A>T (IVS6-2A>T); ClinVar=VCV000635388; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1083 ! BFTC-905
SX   Female
AG   51Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 13
//
RX   PubMed=25566959; DOI=10.1007/s13277-014-2959-9;
RA   Greife A., Tukova J., Steinhoff C., Scott S.D., Schulz W.A.,
RA   Hatina J.;
RT   "Establishment and characterization of a bladder cancer cell line with
RT   enhanced doxorubicin resistance by mevalonate pathway activation.";
RL   Tumor Biol. 36:3293-3300(2015).
//